These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 8889850)

  • 1. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P; Nguyen H; Barbier A; Baron R
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K; Takeshita N; Takano M
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.
    Mattsson JP; Skyman C; Palokangas H; Väänänen KH; Keeling DJ
    J Bone Miner Res; 1997 May; 12(5):753-60. PubMed ID: 9144341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possible mechanism of the specific action of bisphosphonates on osteoclasts].
    Udagawa N
    Nihon Rinsho; 2003 Feb; 61(2):207-12. PubMed ID: 12638209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase.
    Mattsson JP; Keeling DJ
    Biochim Biophys Acta; 1996 Apr; 1280(1):98-106. PubMed ID: 8634321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
    Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
    Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
    Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
    J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
    Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
    Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vacuolar-type H+-ATPase-mediated acidosis promotes in vitro osteoclastogenesis via modulation of cell migration.
    Kim JM; Min SK; Kim H; Kang HK; Jung SY; Lee SH; Choi Y; Roh S; Jeong D; Min BM
    Int J Mol Med; 2007 Mar; 19(3):393-400. PubMed ID: 17273786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.
    Gagliardi S; Gatti PA; Belfiore P; Zocchetti A; Clarke GD; Farina C
    J Med Chem; 1998 May; 41(11):1883-93. PubMed ID: 9599238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
    Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
    J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles.
    Bekker PJ; Gay CV
    J Bone Miner Res; 1990 Jun; 5(6):569-79. PubMed ID: 2166421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of proton transport in bone-derived membrane vesicles.
    Mattsson JP; Wallmark B; Lorentzon P; Keeling DJ
    Acta Physiol Scand Suppl; 1992; 607():253-7. PubMed ID: 1449069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.